LYZZ Capital
Venture capitalShanghai · Seed–Series A · 5 people tracked
Find your way into LYZZ Capital
54 people in our graph share verified history with the LYZZ Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
LYZZ Capital dedicates itself to healthcare investing across venture and private equity, backing talent, assets, and technologies on a global basis. The firm targets areas addressing unmet medical needs and large market potential, with a strong focus on China. Its team is drawn from leading pharmaceutical and biotech companies as well as Wall Street firms, combining scientific, medical, and financial expertise. With more than two decades of biotech investment experience and over fifteen years of activity in China, LYZZ invests out of both USD and RMB funds, seeking opportunities that connect global innovation with Chinese market demand.
Source: firm website, verified Aug 3, 2026.
Team · 5 people
from public directoriesWhat they invest in
from 9 of 14 portfolio companiesBiotech ×8Healthtech ×6Medical Devices ×5Deep Tech ×2Hardware ×2AgTech ×1AI & Machine Learning ×1Cleantech ×1
HQs:United States×6China×3
Investments · 14 tracked
founders shown can be your intro pathBy year:2025 · 12021 · 12 dated
A biopharmaceutical company developing oncology treatments including EGFR-targeting small molecule drugs for lung cancer with CNS penetration, and expanding into cell immunotherapy through licensed partnerships for NK cell and CAR-T therapies targeting solid tumors and hematologic malignancies.
BiotechDeep TechHealthtechMedical DevicesShanghai, CN
Xian-ping LU(Founder)in
Co-investorsLAVLilly Asia VenturesVertex Ventures China
Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
David Michael Salter(Executive Officer, Director)Mike Salter(CEO/President)inEugene Chen(Director)Keith Brown(Executive Officer, Director)Joel Rotroff(Director)
BoardCourt Turner(Director)
Co-investorsArboretum Ventures
MicroTech Medical provides medical information services in China, with operational headquarters in Hangzhou and a principal place of business in Hong Kong.
Digital HealthHardwareMedical DevicesHangzhou, CN
Co-investorsLAVLilly Asia VenturesQiming Venture Partners
Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy.
BiotechHealthtechMedical DevicesEncinitas, US
Craig C. Chambliss(Executive Officer, Director)inCraig Chambliss(Founder)in
BoardDavid F. Hale(Director)Cam Garner(Director)Yong Zhang(Director)Kevin Li(Director)in
Co-investorsOrbiMed
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsB Capital GroupBoehringer Ingelheim Venture FundCity Hill VenturesDelos CapitalKorea Investment PartnersLumira Ventures+1 more
.jpeg){kind=logo}
QpexBio develops anti-infective drugs designed to overcome multidrug resistance, improving existing drug classes and discovering new ones for use in combination with known anti-infectives against drug-resistant bacteria.
BiotechHealthtechSan Diego, US
Michael N. Dudley(Executive Officer, Director)inTerry Gould(Director)Daniel Burgess(Director)
BoardCarol Gallagher(Director)inDouglas Reed(Director)inKevin Li(Director)in
Co-investorsHatteras Venture PartnersNew Enterprise Associates (NEA)Adams Street Partners
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersAbingworthFidelity Investments+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Allotera TherapeuticsWxyuannuoYun300Zhiyunyilu
Portfolio news
latest coverage across their companiesWugen · bizjournals.com · Jul 10, 2026
Neurelis · morningstar.com · Jun 15, 2026
Frequently asked questions
- How many investments has LYZZ Capital made?
- LYZZ Capital has 14 tracked investments, including 1 dated in the last 24 months.
- What stage does LYZZ Capital invest at?
- LYZZ Capital invests at the Seed, Series A stages.
- What sectors does LYZZ Capital focus on?
- LYZZ Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is LYZZ Capital located?
- LYZZ Capital is headquartered in Shanghai, CN.
- Who does LYZZ Capital co-invest with?
- LYZZ Capital most often shares deals with LAV, Lilly Asia Ventures, OrbiMed, among 10 tracked co-investors.
Similar investors
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Wavemaker 360 is a healthcare-focused venture capital firm that backs entrepreneurs building disruptive companies transforming the healthcare industry. Its limited partners are largely individuals with significant healthcare industry experience.
HealthQuad is a healthcare-focused investment firm that partners with entrepreneurs building category-defining healthcare businesses, leveraging its healthcare network and clinical/operating expertise.
Next Ventures is an investment firm that backs founders building solutions to improve health care access and enhance human capability.
CABHI (Centre for Aging + Brain Health Innovation) is a pan-Canadian organization that funds and supports researchers, innovators, and startups working on brain health and aging solutions, and helps healthcare and community organizations adopt them.